Discovery of Novel C-glycosyl Pyranose-Based Sulfonium and Selenonium Salts Targeting α-Glucosidase with Potent Antihyperglycemic Activity
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c02873 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Jiahui Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Glycoside Hydrolase Inhibitors, alpha-Glucosidases, Sulfonium Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Jiangsu Shuang Chuang team.
Abstract (Originalsprache)
α-Glucosidase inhibitors mitigate postprandial hyperglycemia by delaying carbohydrate hydrolysis. Guided by the principle of bioisosterism, we transformed an acid-labile benzylidene acetal sulfonium scaffold into acid-stable C-glycosyl pyranose–based sulfonium and selenonium salts. The lead, 38f, inhibited rat intestinal maltase and sucrase with IC 50 values of 0.10 and 0.08 μM, respectively, outperforming acarbose and voglibose, and showed excellent stability in simulated gastric fluid and intestinal fluid. In vivo, 38f delivered robust, dose-efficient glucose lowering: at 1–3 mg/kg, it markedly suppressed postprandial excursions in normal ICR mice and reduced fasting glucose in STZ-diabetic mice (3 mg/kg 32.8% vs acarbose 50 mg/kg 24.3%). Across OGTT/ITT and maltose/sucrose tolerance tests, 38f improved glycemic end points, liver glycogen, and HbA1c. Kinetic analyses support competitive inhibition of α-glucosidase. A 14-day subacute study (≤500 mg/kg) indicated an acceptable safety profile without hepatic or renal toxicity. These acid-resistant C-glycosyl pyranose cationic glycomimetics merit further development as antidiabetic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, P. R. China.
- State Key Laboratory of Natural Medicines and Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
- Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Korea.
- Faculty of Pharmacy, Kinki University, 3-4-1 Kowakae, Higashi-osaka, Osaka 577-8502, Japan.
- Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, P. R. China.
ORCID-Profile: Zhimei Wang, Wei Li, Genzoh Tanabe, Weijia Xie
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Jiangsu Shuang Chuang team
Zitieren
APA
Zhou, J., Jin, S., Yi, J., Li, Y., Tao, W., Li, Y., Wang, Z., Li, W., Jiang, H., Tanabe, G., Muraoka, O., Wu, L., & Xie, W. (2026). Discovery of Novel C-glycosyl Pyranose-Based Sulfonium and Selenonium Salts Targeting α-Glucosidase with Potent Antihyperglycemic Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02873
Vancouver
Zhou J, Jin S, Yi J, Li Y, Tao W, Li Y, et al. Discovery of Novel C-glycosyl Pyranose-Based Sulfonium and Selenonium Salts Targeting α-Glucosidase with Potent Antihyperglycemic Activity. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02873
BibTeX
@article{Zhou2026,
author = {Zhou, Jiahui and Jin, Shuqing and Yi, Jiahao and Li, Yaojia and Tao, Wenxiang and Li, Yu and Wang, Zhimei and Li, Wei and Jiang, Hulin and Tanabe, Genzoh and Muraoka, Osamu and Wu, Liang and Xie, Weijia},
title = {Discovery of Novel C-glycosyl Pyranose-Based Sulfonium and Selenonium Salts Targeting α-Glucosidase with Potent Antihyperglycemic Activity},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c02873}
}
EUVIMED